At Memorial Sloan Kettering (MSK), we're not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we're driving excellence and improving outcomes. We're treating cancer, one patient at a time. Join us and make a difference every day.
In compliance with applicable New York and New Jersey State regulatory authorities, COVID-19 vaccination (2 doses of either the Pfizer or Moderna vaccine or one dose of the Johnson & Johnson vaccine) is mandatory for all MSK employees, contingent workers, and volunteers. Exceptions are permitted for those employees who request and receive an approved medical or fully remote exemption.
*Staff working at a MSK New Jersey location must be up to date with COVID-19 vaccination, which includes having completed the primary COVID-19 vaccination series and booster once eligible as mandated by New Jersey State. All New Jersey staff not yet eligible for a booster must receive a booster within 3 weeks of becoming eligible as a condition of continued employment at MSK.
Note: Individuals are eligible to receive a COVID-19 booster five months after receiving the second dose of either the Pfizer or Moderna vaccine or two months after the J&J vaccine.
Memorial Sloan Kettering Cancer Center (MSK) is one of the world's premier cancer centers, committed to exceptional patient care, leading-edge research, and superb educational programs. The blending of research with patient care is at the heart of everything we do. The institution is a comprehensive cancer center whose purposes are the treatment and control of cancer, the advancement of biomedical knowledge through laboratory and clinical research, and the training of scientists, physicians and other health care workers.
A postdoctoral position is currently available in the laboratory of Dr. Jonathan Coleman in the Department of Surgery at MSKCC. Our lab focuses on understanding genomic/transcriptomic alterations and their association with the tumor immune landscape in urothelial cancer and on developing minimally invasive surgical procedures that enhance immunotherapy outcomes in multiple cancers.
The ideal candidate will have:
PhD or MD in oncology, cell biology or related fields with a preference for a background in immunotherapy/immunology,
Passion for science, and a desire to advance the understanding and treatment of cancer.
A highly organized and self-directed individual with strong interpersonal skills and the ability to work in a dynamic environment is desired.
Please include CV, brief statement of research interests, and names and details of three references in your application. Please direct questions to Kwanghee Kim, Assistant Attending Biologist (email@example.com).
Rosenzweig B, Corradi R et al. Neoadjuvant Vascular-Targeted Photodynamic Therapy Improves Survival and Reduces Recurrence and Progression in a Mouse Model of Urothelial Cancer. Sci Rep. 2021 Mar 1;11(1):4842.
Alvim R, Nagar K et al. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model. Eur Urol Focus. 2021 Mar;7(2):472-478.
Kim K, Hu W et al. Modeling Biological and Genetic Diversity in Upper Tract Urothelial Carcinoma with Patient Derived Xenografts. Nat Commun. 2020 Apr 24;11(1):1975.
At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes. For the 28th year, MSK has been named a top hospital for cancer by U.S. News & World Report. We are proud to be on Becker’s Healthcare list as one of the 150 Great Places to Work in Healthcare in 2018, as well as one of Glassdoor’s Employees’ Choice Best Place to Work for 2018. We’re treating cancer, one patient at a time. Join us and make a difference every day.